Clinical trial · Observational
Myeloid Cell Reprogramming in Thyroid Carcinoma
Myeloid Cell Reprogramming in the Context of Radioiodine Therapy in Patients With Non-Medullary Thyroid Carcinoma
NCT03397238CI-TRIAL-00056420completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study investigates the reprogramming of myeloid cells in patients with thyroid carcinoma. The investigators hypothesize that tumor-derived factors change the function of myeloid cells (peripheral blood and bone marrow-derived) in such a way that these immune cells promote tumor growth rather than combat the tumor.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (5)
- label
- Non-metastatic TC
- description
- blood withdrawal, bone marrow aspiration
- label
- Metastatic TC
- description
- blood withdrawal, bone marrow aspiration
- label
- MNG surgery
- description
- blood withdrawal, bone marrow aspiration
- label
- MNG RAI treatment
- description
- blood withdrawal
- label
- Healthy volunteers
- description
- blood withdrawal
Primary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Group 1: Subject is newly diagnosed with TC, therapy-naive and is planned to receive conventional treatment by surgery followed by RAI; no evidence of local or distant metastases * Group 2: Subject has TC with evidence of distant metastases (either newly diagnosed or therapy-naive or patients with persistent or recurrent disease); at least 4 months since the previous treatment with RAI if applicable * Group 3: Subject is diagnosed with MNG, is euthyroid, and is planned to undergo surgery - Group 4: Subject is diagnosed with MNG, is euthyroid, and is planned to receive RAI treatment \- Group 5: Healthy individuals who are euthyroid and have no evidence of thyroid disease Exclusion Criteria: * Mentally incompetent * Pregnant, trying to become pregnant or breastfeeding * Known inflammatory or infectious diseases or an immunosuppressive status * Using medication interfering with the immune system * Reduced platelet counts or other conditions associated with an increased risk of bleeding * Severe comorbidities: other active malignancy (except for basal cell carcinoma) * Serious psychiatric pathology * A self-reported alcohol consumption of \>21 units per week
References
Publications (0)
Data not yet available
No reference posted for this study.